Reverse Your Reliance on 503Bs for Compounded Sterile Products

The Future of Pharmacy, presented by Omnicell

Omnicell에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Omnicell 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

2y ago 33:03

MP3•에피소드 홈

Health systems are continuously being challenged to ensure IV preparations are prepared safely and accurately while complying with increasingly complex regulations. As a result, many rely on 503B outsourcing pharmacies to provide the vast majority of their pre-mixed compounded sterile products. But as product shortages and pricing fluctuations in the supply chain become more acute, rather than provide relief, 503Bs actually can put more pressure on pharmacy staffs and budget.

Joining host Ken Perez to discuss are pharmacy leaders who met those challenges by going against the trend – by insourcing their sterile compounding, with a twist.

Joseph J. DiCubellis, RPh, MPH, Senior Director of Pharmacy Services for the University of Maryland Medical System and Senior Director of Pharmacy, University of Maryland Medical Center
Yevgeniya Kogan-Hardesty, PharmD, BCSCP, Sterile Compounding, Pharmacy Manager, University of Maryland Medical Center

23 에피소드

#Tech #Fitness #Business #Omnicell #Healthcare #Healthtech #Pharmacy #Technology #Drug Costs #Prescription Drugs #Medical